Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Bayer : Recent Findings from Bayer Has Provided New Data on Melanoma (Super-enhancers define a proliferative PGC-1a-expressing melanoma subgroup sensitive to...

share with twitter share with LinkedIn share with facebook
share via e-mail
10/19/2017 | 10:10pm CEST

Recent Findings from Bayer Has Provided New Data on Melanoma (Super-enhancers define a proliferative PGC-1a-expressing melanoma subgroup sensitive to BET inhibition)

By a News Reporter-Staff News Editor at Cancer Weekly -- Researchers detail new data in Oncology - Melanoma. According to news reporting from Berlin, Germany, by NewsRx journalists, research stated, "Metabolic changes are linked to epigenetic reprogramming and play important roles in several tumor types. PGC-1a is a transcriptional coactivator controlling mitochondrial biogenesis and is linked to oxidative phosphorylation."

The news correspondents obtained a quote from the research from Bayer, "We provide evidence that melanoma models with elevated PGC-1a levels are characteristic of the proliferative phenotype and are sensitive to bromodomain and extra-terminal domain (BET) inhibitor treatment. A super-enhancer region highly occupied by the BET family member BRD4 was identified for the PGC-1a gene. BET inhibitor treatment prevented this interaction, leading to a dramatic reduction of PGC-1a expression. Accordingly, BET inhibition diminished respiration and mitochondrial function in cells. In vivo, melanoma models with high PGC-1a expression strongly responded to BET inhibition by reduction of PGC-1a and impaired tumor growth."

According to the news reporters, the research concluded: "Altogether, our findings identify epigenetic regulatory elements that define a subset of melanomas with high sensitivity to BET inhibition, which opens up the opportunity to define melanoma patients most likely to respond to this treatment, depending on their tumor characteristics.Oncogene advance online publication, 9 October."

For more information on this research see: Super-enhancers define a proliferative PGC-1a-expressing melanoma subgroup sensitive to BET inhibition. Oncogene, 2017;():. (Nature Publishing Group - www.nature.com/; Oncogene - www.nature.com/onc/)

Our news journalists report that additional information may be obtained by contacting K.A. Gelato, Drug Discovery, Bayer AG, Berlin, Germany. Additional authors for this research include L. Schockel, O. Klingbeil, T. Ruckert, R. Lesche, J. Toedling, E. Kalfon, M. Heroult, P. Lejeune, U. Monning, A.E. Fernandez-Montalvan, S. Baurle, S. Siegel and B. Haendler (see also Oncology - Melanoma).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1038/onc.2017.325. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Berlin, Europe, Germany, Melanoma, Oncology.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BAYER
10/19 BAYER : Recent Findings from Bayer Has Provided New Data on Melanoma (Super-enha..
10/19 BAYER : submits its extended half - life hemophilia a compound for marketing aut..
10/18 BAYER : to fund three youth-led food security projects
10/17 BAYER : foundations bring tech pioneers physicians and social entrepreneurs to t..
10/16 BAYER : Health and Human Services Department (HHS); Food and Drug Administration..
10/14DJBAYER : Unloads Assets to Aid Deal -- WSJ
10/13 BASF CEO says to look at more seed M&A after Bayer deal
10/13 Bayer sells units to be able to complete Monsanto takeover
10/13 BAYER : foundations bring tech pioneers, physicians and social entrepreneurs to ..
More news
News from SeekingAlpha
10/20 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2017 Update
10/17 Monsanto Ending On A Position Of Strength
10/16 BASF (BASFY) To Acquire Significant Parts Of Bayer's (BAYZF) Seed And Non-Sel..
10/14 BASF Buys Bayer's Crop Science Assets At A Fair Price
10/13 WALL STREET BREAKFAST : The Beat Goes On For Global Stocks As Records Continue T..
Financials (€)
Sales 2017 47 846 M
EBIT 2017 9 231 M
Net income 2017 5 397 M
Debt 2017 12 235 M
Yield 2017 2,34%
P/E ratio 2017 19,53
P/E ratio 2018 17,71
EV / Sales 2017 2,31x
EV / Sales 2018 2,20x
Capitalization 98 159 M
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Technical analysis trends BAYER
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 121 €
Spread / Average Target 1,9%
EPS Revisions
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER19.94%115 989
JOHNSON & JOHNSON23.29%377 585
NOVARTIS13.50%226 453
ROCHE HOLDING LTD.5.55%215 760
PFIZER11.58%213 372